Stage 8 · ACLS Lab

Drugs in the body

Give a drug and watch what it does, end to end: the push and the flush, the slow trip to the heart during CPR, the receptor, channel or node it acts on, the change it makes, and what the monitor shows.

Guidelines: AHA 2020 with the 2023 update and confirmed 2025 changes; PALS 2020 with the 2025 pediatric updates

Reflects the AHA 2020 adult algorithms with the 2023 focused update, updated for the 2025 AHA Guidelines for CPR and ECC where the change could be confirmed; acute coronary syndromes follow the 2025 ACC/AHA guideline and stroke the 2026 AHA/ASA guideline. Pediatric content follows the AHA 2020 PALS algorithms with the 2025 AHA/AAP pediatric updates where confirmed.

The explorer

The animated explorer needs JavaScript. Every drug's journey is written out step by step below.

Every drug, step by step

The same journeys as the explorer, in words. The bead and label colours follow the syringe label colours used in anaesthesia where the standard has a class for the drug (vasopressors violet, anticholinergics green, opioids blue, local anaesthetics grey; stripes for opioid antagonists and hypotensive agents); other drugs are white. The monitor in the explorer shows a simulated patient with round illustrative numbers, not targets.

Epinephrine The arrest vasopressor

Adult cardiac arrest: VF, CPR in progress. Watch it · Doses and cautions

  1. Give: Give. Epinephrine: 1 mg, IV/IO. In VF or pulseless VT it follows the second shock; in asystole or PEA it is given as soon as possible. Drug in the blood: none; Aortic pressure between compressions: moderate; Coronary perfusion pressure: moderate. Monitor: VF, CPR in progress.
  2. Give: Flush. A saline flush pushes the dose out of the arm vein and into the central circulation. Without it, much of the dose can sit in the arm. Drug in the blood: low; Aortic pressure between compressions: moderate; Coronary perfusion pressure: moderate. Monitor: VF, CPR in progress.
  3. Travel: To the heart, during CPR. No heartbeat: the only flow is what compressions make. The dose creeps toward the heart a little with each compression, far more slowly than in a beating heart, and every pause in compressions stalls it. Drug in the blood: moderate; Aortic pressure between compressions: moderate; Coronary perfusion pressure: moderate. Monitor: VF, CPR in progress.
  4. Travel: Round the circulation, during CPR. Through the right heart and the lungs, then out of the left heart and out to the arteries of the limbs and gut. Each compression pushes it on. Drug in the blood: very high; Aortic pressure between compressions: moderate; Coronary perfusion pressure: moderate. Monitor: VF, CPR in progress.
  5. Site of action: Alpha-1 receptors. In the walls of the peripheral arteries it binds alpha-1 receptors on the smooth muscle. The muscle contracts and the arteries narrow. Close-up: Alpha-1 receptor, artery wall. Drug in the blood: very high; Aortic pressure between compressions: moderate; Coronary perfusion pressure: moderate. Monitor: VF, CPR in progress.
  6. Effect: Coronary perfusion pressure rises. With the periphery squeezed, less of each compression's output runs off into the limbs and gut. Aortic pressure stays higher between compressions, and that pressure is what drives blood into the coronary arteries. Close-up: Narrowed artery. Drug in the blood: very high; Aortic pressure between compressions: high; Coronary perfusion pressure: high. Monitor: VF, CPR in progress.
  7. Site of action: Beta-1 receptors. It also binds beta-1 receptors in the heart. In arrest that adds oxygen demand to starving muscle; once the heart beats again it raises rate and force, and can provoke ectopy and recurrent VF. Close-up: Beta-1 receptor, heart muscle. Drug in the blood: very high; Aortic pressure between compressions: high; Coronary perfusion pressure: high. Monitor: VF, CPR in progress.
  8. Monitor: What the monitor shows. No new rhythm: epinephrine does not defibrillate. It gives compressions, shocks and the heart's own recovery a better chance. It raises the chance of ROSC; it has not been shown to improve survival with good neurological function. Close-up: Narrowed artery. Drug in the blood: high; Aortic pressure between compressions: high; Coronary perfusion pressure: high. Monitor: VF, CPR in progress.
  9. Effect: It wears off. Within minutes the drug is taken up and broken down, and the pressure gain fades. That is why the dose is repeated every 3–5 minutes for as long as the arrest lasts. Close-up: Artery relaxing. Drug in the blood: low; Aortic pressure between compressions: moderate; Coronary perfusion pressure: moderate. Monitor: VF, CPR in progress.
Amiodarone Antiarrhythmic for shock-refractory VF/pVT and stable VT

Adult cardiac arrest: VF that persists after shocks. Watch it · Doses and cautions

  1. Give: Give. Amiodarone: 300 mg bolus, IV/IO. For VF or pulseless VT that persists after shocks. Repeat: second dose 150 mg. Drug in the blood: none; Refractory period: moderate. Monitor: Shock-refractory VF.
  2. Give: Flush. A saline flush pushes the dose out of the arm vein and into the central circulation. Without it, much of the dose can sit in the arm. Drug in the blood: low; Refractory period: moderate. Monitor: Shock-refractory VF.
  3. Travel: To the heart, during CPR. No heartbeat: the only flow is what compressions make. The dose creeps toward the heart a little with each compression, far more slowly than in a beating heart, and every pause in compressions stalls it. Drug in the blood: moderate; Refractory period: moderate. Monitor: Shock-refractory VF.
  4. Travel: Round the circulation, during CPR. Through the lungs and out of the left heart into the coronary arteries. The drug has to reach the fibrillating muscle, and compressions are the only thing perfusing it. Drug in the blood: very high; Refractory period: moderate. Monitor: Shock-refractory VF.
  5. Site of action: Potassium channels. In ventricular cells it blocks potassium channels, the channels that carry repolarization (phase 3). It also blocks some sodium and calcium channels and beta receptors. Close-up: Potassium channels, ventricular cell. Drug in the blood: very high; Refractory period: moderate. Monitor: Shock-refractory VF.
  6. Effect: A longer action potential. With fewer potassium channels open, the cell takes longer to repolarize. The action potential, and the refractory period with it, lengthen. Close-up: Action potential, before and after. Drug in the blood: very high; Refractory period: high. Monitor: Shock-refractory VF.
  7. Effect: Re-entry runs into refractory tissue. VF is kept alive by wavelets that re-enter tissue as soon as it recovers. When tissue stays refractory longer, a returning wavefront more often meets muscle that cannot fire yet, and dies out. Close-up: A re-entrant wavelet. Drug in the blood: very high; Refractory period: high. Monitor: Shock-refractory VF.
  8. Monitor: The next shock. The drug rarely stops VF by itself; the shock does. Amiodarone makes VF less likely to persist or come back after a shock. It improves ROSC and survival to hospital admission; it has not been shown to improve survival to discharge. Close-up: A re-entrant wavelet. Drug in the blood: very high; Refractory period: high. Monitor: ROSC: sinus tachycardia.
Lidocaine The alternative to amiodarone

Adult cardiac arrest: VF that persists after shocks. Watch it · Doses and cautions

  1. Give: Give. Lidocaine: 1–1.5 mg/kg first dose, IV/IO. For VF or pulseless VT that persists after shocks. Repeat: 0.5–0.75 mg/kg, to 3 mg/kg in total. Drug in the blood: none; Refractory period: moderate. Monitor: Shock-refractory VF.
  2. Give: Flush. A saline flush pushes the dose out of the arm vein and into the central circulation. Without it, much of the dose can sit in the arm. Drug in the blood: low; Refractory period: moderate. Monitor: Shock-refractory VF.
  3. Travel: To the heart, during CPR. No heartbeat: the only flow is what compressions make. The dose creeps toward the heart a little with each compression, far more slowly than in a beating heart, and every pause in compressions stalls it. Drug in the blood: moderate; Refractory period: moderate. Monitor: Shock-refractory VF.
  4. Travel: Round the circulation, during CPR. Through the lungs and out of the left heart into the coronary arteries. The drug has to reach the fibrillating muscle, and compressions are the only thing perfusing it. Drug in the blood: very high; Refractory period: moderate. Monitor: Shock-refractory VF.
  5. Site of action: Sodium channels. It binds fast sodium channels, mostly while they are open or inactivated. So it gathers in cells that fire fast or sit partly depolarized, such as ischemic muscle, and largely spares normal tissue. Close-up: Sodium channels, ischemic cell. Drug in the blood: very high; Refractory period: moderate. Monitor: Shock-refractory VF.
  6. Effect: Slower upstroke in damaged tissue. In the ischemic cells phase 0 rises more slowly and the cells recover later, so the threshold for re-entry rises there. Close-up: Action potential, ischemic cell. Drug in the blood: very high; Refractory period: high. Monitor: Shock-refractory VF.
  7. Effect: Re-entry runs into refractory tissue. VF is kept alive by wavelets that re-enter tissue as soon as it recovers. When tissue stays refractory longer, a returning wavefront more often meets muscle that cannot fire yet, and dies out. Close-up: A re-entrant wavelet. Drug in the blood: very high; Refractory period: high. Monitor: Shock-refractory VF.
  8. Monitor: The next shock. The drug rarely stops VF by itself; the shock does. Lidocaine makes VF less likely to persist or come back after a shock. It improves ROSC and survival to hospital admission; it has not been shown to improve survival to discharge. Close-up: A re-entrant wavelet. Drug in the blood: very high; Refractory period: high. Monitor: ROSC: sinus tachycardia.
Magnesium sulfate For torsades de pointes

Torsades de pointes with a long QT. Watch it · Doses and cautions

  1. Give: Give. Magnesium sulfate: 1–2 g, IV/IO, diluted. For torsades de pointes with a long QT. Without a pulse, defibrillate first; magnesium is the add-on. Drug in the blood: none; Afterdepolarizations: very high. Monitor: Torsades de pointes.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Afterdepolarizations: very high. Monitor: Torsades de pointes.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Afterdepolarizations: very high. Monitor: Torsades de pointes.
  4. Site of action: The trigger: early afterdepolarizations. A long QT leaves the cell lingering in its plateau. Calcium channels can reopen and give an extra upstroke, an early afterdepolarization. If it reaches threshold it fires a premature beat, and that can launch torsades. Close-up: Ventricular action potential, long QT. Drug in the blood: very high; Afterdepolarizations: very high. Monitor: Torsades de pointes.
  5. Effect: The trigger is damped. Magnesium damps that calcium current (the likeliest explanation). The afterdepolarizations shrink below threshold, so the trigger beats stop. Close-up: Afterdepolarizations suppressed. Drug in the blood: very high; Afterdepolarizations: low. Monitor: Torsades de pointes.
  6. Monitor: Torsades stops; the QT stays long. The torsades stops, but the QT may stay long: the substrate is still there. Correct the cause (QT-prolonging drugs, low potassium or magnesium). If it keeps returning, raising the heart rate shortens the QT: isoproterenol or overdrive pacing. Close-up: Afterdepolarizations suppressed. Drug in the blood: very high; Afterdepolarizations: low. Monitor: Sinus rhythm, long QT.
Atropine First drug for symptomatic bradycardia

Sinus bradycardia

Symptomatic sinus bradycardia. Watch it · Doses and cautions

  1. Give: Give. Atropine: 1 mg bolus, IV. Symptomatic sinus bradycardia. Drug in the blood: none; Vagal brake: very high; Heart rate: low. Monitor: Symptomatic sinus bradycardia.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Vagal brake: very high; Heart rate: low. Monitor: Symptomatic sinus bradycardia.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Vagal brake: very high; Heart rate: low. Monitor: Symptomatic sinus bradycardia.
  4. Site of action: The vagal brake. At the sinus and AV nodes the vagus nerve releases acetylcholine onto M2 muscarinic receptors. They open potassium channels and slow the pacemaker's drift to threshold. Close-up: M2 receptors, sinus node. Drug in the blood: very high; Vagal brake: very high; Heart rate: low. Monitor: Symptomatic sinus bradycardia.
  5. Site of action: Atropine blocks M2. Atropine sits in the M2 receptors, so acetylcholine cannot bind. The brake is off. Close-up: Atropine in the M2 receptors. Drug in the blood: very high; Vagal brake: low; Heart rate: moderate. Monitor: Symptomatic sinus bradycardia.
  6. Effect: Faster pacemaker, faster AV node. Pacemaker cells now drift to threshold faster and the AV node conducts faster. The heart rate rises. Close-up: Sinus node action potential. Drug in the blood: very high; Vagal brake: low; Heart rate: high. Monitor: Sinus rhythm.
  7. Monitor: If it is not enough. It can be repeated every 3–5 minutes, to 3 mg total. If the patient stays unstable, move on to pacing or a chronotrope infusion. Close-up: Sinus node action potential. Drug in the blood: very high; Vagal brake: low; Heart rate: high. Monitor: Sinus rhythm.

Block below the node

Third-degree AV block with a ventricular escape rhythm. Watch it · Doses and cautions

  1. Give: Give. Atropine: 1 mg bolus, IV. Third-degree block with a slow, wide escape rhythm: watch what it can and cannot do. Drug in the blood: none; Vagal brake: very high; Ventricular rate: low. Monitor: Third-degree block, wide escape.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Vagal brake: very high; Ventricular rate: low. Monitor: Third-degree block, wide escape.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Vagal brake: very high; Ventricular rate: low. Monitor: Third-degree block, wide escape.
  4. Site of action: The vagal brake. At the sinus and AV nodes the vagus nerve releases acetylcholine onto M2 muscarinic receptors. They open potassium channels and slow the pacemaker's drift to threshold. Close-up: M2 receptors, sinus node. Drug in the blood: very high; Vagal brake: very high; Ventricular rate: low. Monitor: Third-degree block, wide escape.
  5. Site of action: Atropine blocks M2. Atropine sits in the M2 receptors, so acetylcholine cannot bind. The brake is off. Close-up: Atropine in the M2 receptors. Drug in the blood: very high; Vagal brake: low; Ventricular rate: low. Monitor: Third-degree block, wide escape.
  6. Effect: The block is below the vagus. The sinus node speeds up, but the block is in the His–Purkinje system, which the vagus does not reach. Nothing gets through any faster: the ventricular escape rate stays where it was, and the block can even worsen. Close-up: Where the vagus reaches. Drug in the blood: very high; Vagal brake: low; Ventricular rate: low. Monitor: Atria faster; escape unchanged.
  7. Monitor: Pace. Atropine will not fix this rhythm. Prepare transcutaneous pacing, or start a chronotrope infusion; never let atropine delay pacing for a wide escape rhythm. Close-up: Where the vagus reaches. Drug in the blood: very high; Vagal brake: low; Ventricular rate: low. Monitor: Atria faster; escape unchanged.
Dopamine infusion Chronotrope and pressor

Symptomatic bradycardia, unresponsive to atropine. Watch it · Doses and cautions

  1. Give: Give. Dopamine infusion: 5–20 mcg/kg per minute, IV infusion. Symptomatic bradycardia when atropine has not worked: an alternative to pacing. Drug in the blood: none; Beta-1: rate and force: none; Alpha-1: vessel squeeze: none. Monitor: Bradycardia; atropine failed.
  2. Travel: A steady level. An infusion builds up a steady level over minutes, instead of arriving as one bolus. Drug in the blood: moderate; Beta-1: rate and force: none; Alpha-1: vessel squeeze: none. Monitor: Bradycardia; atropine failed.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: moderate; Beta-1: rate and force: low; Alpha-1: vessel squeeze: none. Monitor: Bradycardia; atropine failed.
  4. Site of action: Low in the range: beta-1. At the lower end of the range, beta-1 effects lead: the sinus node fires faster and the muscle contracts harder. Close-up: Receptors stimulated, by dose. Drug in the blood: moderate; Beta-1: rate and force: high; Alpha-1: vessel squeeze: low. Monitor: Rate rising.
  5. Effect: Higher: alpha-1 joins in. Turn it up and alpha-1 vasoconstriction joins in: blood pressure rises further, at the cost of more work for the heart and more risk of tachyarrhythmia. Close-up: Receptors stimulated, by dose. Drug in the blood: very high; Beta-1: rate and force: very high; Alpha-1: vessel squeeze: high. Monitor: Sinus rhythm, better pressure.
  6. Monitor: Titrate. 5–20 mcg/kg per minute, titrate to response; taper slowly. Correct volume first: pressors cannot squeeze an empty tank. Close-up: Receptors stimulated, by dose. Drug in the blood: high; Beta-1: rate and force: high; Alpha-1: vessel squeeze: high. Monitor: Sinus rhythm, better pressure.
Epinephrine infusion Chronotrope and pressor by infusion

Symptomatic bradycardia, unresponsive to atropine. Watch it · Doses and cautions

  1. Give: Give. Epinephrine infusion: 2–10 mcg per minute, IV infusion. Symptomatic bradycardia when atropine has not worked: an alternative to pacing. Drug in the blood: none; Beta-1: rate and force: none; Alpha-1: vessel squeeze: none. Monitor: Bradycardia; atropine failed.
  2. Travel: A steady level. An infusion builds up a steady level over minutes, instead of arriving as one bolus. Drug in the blood: moderate; Beta-1: rate and force: none; Alpha-1: vessel squeeze: none. Monitor: Bradycardia; atropine failed.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: moderate; Beta-1: rate and force: low; Alpha-1: vessel squeeze: none. Monitor: Bradycardia; atropine failed.
  4. Site of action: Low in the range: beta-1. At low rates beta-1 effects dominate: the sinus node fires faster and the muscle contracts harder. Close-up: Receptors stimulated, by dose. Drug in the blood: moderate; Beta-1: rate and force: high; Alpha-1: vessel squeeze: low. Monitor: Rate rising.
  5. Effect: Higher: alpha-1 joins in. Higher rates add alpha-1 vasoconstriction: blood pressure rises further, at the cost of more oxygen demand and more risk of tachyarrhythmia. Close-up: Receptors stimulated, by dose. Drug in the blood: very high; Beta-1: rate and force: very high; Alpha-1: vessel squeeze: high. Monitor: Sinus rhythm, better pressure.
  6. Monitor: Titrate. 2–10 mcg per minute, titrate to response. Micrograms per minute for an infusion, milligrams for the arrest bolus: a thousandfold difference. Close-up: Receptors stimulated, by dose. Drug in the blood: high; Beta-1: rate and force: high; Alpha-1: vessel squeeze: high. Monitor: Sinus rhythm, better pressure.
Adenosine Momentary AV block

AV nodal re-entry

Stable regular narrow-complex tachycardia: AV nodal re-entry. Watch it · Doses and cautions

  1. Give: Give. Adenosine: 6 mg rapid push, then a saline flush, IV. Use a vein close to the heart, and record a rhythm strip while you push: the pause is diagnostic. Drug in the blood: none; AV node conduction: very high. Monitor: Regular narrow tachycardia.
  2. Give: Rapid flush. Straight away, a rapid saline flush. The drug is cleared within seconds, so it must reach the heart as one tight bolus. Drug in the blood: very high; AV node conduction: very high. Monitor: Regular narrow tachycardia.
  3. Travel: To the heart. Its half-life is under 10 seconds: red cells and vessel walls take it up almost at once. A slow push or a distant vein, and too little reaches the node. Drug in the blood: high; AV node conduction: very high. Monitor: Regular narrow tachycardia.
  4. Site of action: A1 receptors in the AV node. It binds A1 receptors on AV nodal cells. They open potassium channels and lower cyclic AMP: the cells hyperpolarize, away from threshold. Close-up: A1 receptor, AV nodal cell. Drug in the blood: moderate; AV node conduction: moderate. Monitor: Regular narrow tachycardia.
  5. Effect: Seconds of AV block. For a few seconds the AV node conducts nothing. Expect a pause on the monitor, and warn the patient: a brief sense of doom, chest tightness and flushing are common. Close-up: Hyperpolarized: no firing. Drug in the blood: moderate; AV node conduction: none. Monitor: AV node blocked.
  6. Monitor: The loop breaks. The re-entry loop ran through the AV node. With the node silent for a moment, the loop has nowhere to go and stops. The sinus node takes over. Close-up: Re-entry loop in the AV node, cut. Drug in the blood: none; AV node conduction: very high. Monitor: Sinus rhythm.
  7. Monitor: If nothing happened. No pause at all usually means too little reached the node. The second dose is 12 mg if needed, pushed fast with a flush. Close-up: Re-entry loop in the AV node, cut. Drug in the blood: none; AV node conduction: very high. Monitor: Sinus rhythm.

Atrial flutter

Regular narrow-complex tachycardia at 150/min: atrial flutter with 2:1 conduction. Watch it · Doses and cautions

  1. Give: Give. Adenosine: 6 mg rapid push, then a saline flush, IV. Use a vein close to the heart, and record a rhythm strip while you push: the pause is diagnostic. Drug in the blood: none; AV node conduction: very high. Monitor: Regular narrow tachycardia, 150/min.
  2. Give: Rapid flush. Straight away, a rapid saline flush. The drug is cleared within seconds, so it must reach the heart as one tight bolus. Drug in the blood: very high; AV node conduction: very high. Monitor: Regular narrow tachycardia, 150/min.
  3. Travel: To the heart. Its half-life is under 10 seconds: red cells and vessel walls take it up almost at once. A slow push or a distant vein, and too little reaches the node. Drug in the blood: high; AV node conduction: very high. Monitor: Regular narrow tachycardia, 150/min.
  4. Site of action: A1 receptors in the AV node. It binds A1 receptors on AV nodal cells. They open potassium channels and lower cyclic AMP: the cells hyperpolarize, away from threshold. Close-up: A1 receptor, AV nodal cell. Drug in the blood: moderate; AV node conduction: moderate. Monitor: Regular narrow tachycardia, 150/min.
  5. Effect: Seconds of AV block. For a few seconds the AV node conducts nothing. Expect a pause on the monitor, and warn the patient: a brief sense of doom, chest tightness and flushing are common. Close-up: Hyperpolarized: no firing. Drug in the blood: moderate; AV node conduction: none. Monitor: AV node blocked: flutter waves.
  6. Monitor: The circuit carries on, unmasked. The flutter circuit is in the atrium, so it keeps going. With the node blocked, flutter waves show with no QRS after them; then 2:1 conduction returns. Diagnosis made, rhythm unchanged: now control the rate. Close-up: Flutter circuit in the atrium. Drug in the blood: none; AV node conduction: very high. Monitor: Atrial flutter, 2:1.
  7. Monitor: If nothing happened. No pause at all usually means too little reached the node. The second dose is 12 mg if needed, pushed fast with a flush. Close-up: Flutter circuit in the atrium. Drug in the blood: none; AV node conduction: very high. Monitor: Atrial flutter, 2:1.
Procainamide For stable wide-complex tachycardia

Stable monomorphic VT. Watch it · Doses and cautions

  1. Give: Give. Procainamide: 20–50 mg/min, IV infusion. Stable regular wide-complex tachycardia. Drug in the blood: none; Drug effect: none. Monitor: Stable VT.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Stable VT.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Drug effect: none. Monitor: Stable VT.
  4. Site of action: Sodium and potassium channels. Slows phase 0 (sodium block) and lengthens repolarization (potassium block), slowing conduction and extending refractoriness in atria, ventricles and accessory pathways. Close-up: Sodium and potassium channels. Drug in the blood: very high; Drug effect: moderate. Monitor: Stable VT.
  5. Effect: The effect. Conduction slows and the tissue stays refractory longer, so the re-entry circuit driving the tachycardia can fail. Watch the QRS and the blood pressure while it runs in. Close-up: Sodium and potassium channels. Drug in the blood: very high; Drug effect: very high. Monitor: Sinus rhythm.
  6. Monitor: What the monitor shows. Wider QRS and longer QT: stop when the QRS has widened by half. Close-up: Sodium and potassium channels. Drug in the blood: very high; Drug effect: very high. Monitor: Sinus rhythm.
  7. Monitor: Remember. The stopping rules are part of the dose. Close-up: Sodium and potassium channels. Drug in the blood: very high; Drug effect: high. Monitor: Sinus rhythm.
Sotalol Removed from the 2025 tachycardia algorithm

Stable monomorphic VT (2020 algorithm). Watch it · Doses and cautions

  1. Give: Give. Sotalol: 100 mg (1.5 mg/kg) over 5 minutes, IV. Shown for completeness: the 2025 algorithm no longer lists it. Drug in the blood: none; Drug effect: none. Monitor: Stable VT.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Stable VT.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Drug effect: none. Monitor: Stable VT.
  4. Site of action: Potassium channels and beta receptors. Blocks potassium channels (longer action potential and refractory period) and beta-receptors. Close-up: Potassium channels and beta receptors. Drug in the blood: very high; Drug effect: moderate. Monitor: Stable VT.
  5. Effect: The effect. Cells stay refractory longer, so a re-entry circuit is more likely to fail, and the beta-blockade slows the sinus and AV nodes. Close-up: Potassium channels and beta receptors. Drug in the blood: very high; Drug effect: very high. Monitor: Sinus rhythm.
  6. Monitor: What the monitor shows. On the monitor: longer QT; slower sinus rate. Close-up: Potassium channels and beta receptors. Drug in the blood: very high; Drug effect: very high. Monitor: Sinus rhythm.
  7. Monitor: Remember. Shown here for completeness: the current algorithm uses procainamide or amiodarone. Close-up: Potassium channels and beta receptors. Drug in the blood: very high; Drug effect: high. Monitor: Sinus rhythm.
Beta-blockers (metoprolol, esmolol) Rate control for narrow-complex tachycardia

Atrial fibrillation with a rapid ventricular response. Watch it · Doses and cautions

  1. Give: Give. Metoprolol: 5 mg over 1–2 minutes, IV. Stable narrow-complex tachycardia, or rate control in AF, once vagal maneuvers and adenosine have been tried. Drug in the blood: none; Drug effect: none. Monitor: AF, rapid response.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: AF, rapid response.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Drug effect: none. Monitor: AF, rapid response.
  4. Site of action: Beta-1 receptors on nodal cells. Block beta-1 receptors on nodal cells, flattening the phase 4 slope and slowing AV conduction, so the ventricular rate falls. Close-up: Beta-1 receptors on nodal cells. Drug in the blood: very high; Drug effect: moderate. Monitor: AF, rapid response.
  5. Effect: The effect. The AV node lets fewer of the fibrillating atrium's impulses through, so the ventricles slow. The atria keep fibrillating: this is rate control, not rhythm control. Close-up: Beta-1 receptors on nodal cells. Drug in the blood: very high; Drug effect: very high. Monitor: AF, rate controlled.
  6. Monitor: What the monitor shows. Slower sinus and ventricular rates; longer PR. Close-up: Beta-1 receptors on nodal cells. Drug in the blood: very high; Drug effect: very high. Monitor: AF, rate controlled.
  7. Monitor: Remember. Rate control, not rhythm control. Close-up: Beta-1 receptors on nodal cells. Drug in the blood: very high; Drug effect: high. Monitor: AF, rate controlled.
Diltiazem and verapamil Calcium-channel blockers for narrow tachycardia

Atrial fibrillation with a rapid ventricular response. Watch it · Doses and cautions

  1. Give: Give. Diltiazem: 15–20 mg (0.25 mg/kg) over 2 minutes, IV. Stable narrow-complex tachycardia, or rate control in AF, once vagal maneuvers and adenosine have been tried. Drug in the blood: none; Drug effect: none. Monitor: AF, rapid response.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: AF, rapid response.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Drug effect: none. Monitor: AF, rapid response.
  4. Site of action: L-type calcium channels in the nodes. Block L-type calcium channels, which carry the upstroke (phase 0) in sinus and AV nodal cells. Close-up: L-type calcium channels in the nodes. Drug in the blood: very high; Drug effect: moderate. Monitor: AF, rapid response.
  5. Effect: The effect. Nodal conduction slows, re-entry through the node can stop, and the ventricular response to AF or flutter falls. Close-up: L-type calcium channels in the nodes. Drug in the blood: very high; Drug effect: very high. Monitor: AF, rate controlled.
  6. Monitor: What the monitor shows. Slower ventricular rate in AF and flutter; a longer PR. Close-up: L-type calcium channels in the nodes. Drug in the blood: very high; Drug effect: very high. Monitor: AF, rate controlled.
  7. Monitor: Remember. Never for a wide-complex tachycardia you are not sure about. Close-up: L-type calcium channels in the nodes. Drug in the blood: very high; Drug effect: high. Monitor: AF, rate controlled.
Isotonic crystalloid (fluid bolus) Volume for hypovolemia and shock

Hypovolemic shock. Watch it · Doses and cautions

  1. Give: Give. Isotonic crystalloid: Bolus, often 500–1000 mL, reassessing after each, IV/IO. Hypovolemia: reassess after every bolus. Drug in the blood: none; Drug effect: none. Monitor: Sinus tachycardia, low pressure.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Sinus tachycardia, low pressure.
  3. Travel: Round the circulation. Through the lungs and the left heart, then round the body to the veins and arteries. Drug in the blood: very high; Drug effect: none. Monitor: Sinus tachycardia, low pressure.
  4. Site of action: Filling the heart. Restores circulating volume, so more blood returns to the heart, stretches it, and is pumped out (preload, then stroke volume). Close-up: Filling the heart. Drug in the blood: very high; Drug effect: moderate. Monitor: Sinus tachycardia, low pressure.
  5. Effect: The effect. It cannot help a heart that is already full or failing; too much causes pulmonary edema. Close-up: Filling the heart. Drug in the blood: very high; Drug effect: very high. Monitor: Rate settling.
  6. Monitor: What the monitor shows. Sinus tachycardia slows as volume is restored. Close-up: Filling the heart. Drug in the blood: very high; Drug effect: very high. Monitor: Rate settling.
  7. Monitor: Remember. Push, then look: perfusion, heart rate, blood pressure, liver edge, lungs. Close-up: Filling the heart. Drug in the blood: very high; Drug effect: high. Monitor: Rate settling.
Norepinephrine Vasopressor after ROSC

Hypotension after ROSC, despite fluids. Watch it · Doses and cautions

  1. Give: Give. Norepinephrine: Titrated infusion to a MAP of at least 65 mm Hg, IV infusion. Hypotension after ROSC that persists after fluids. Drug in the blood: none; Drug effect: none. Monitor: Post-ROSC hypotension.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Post-ROSC hypotension.
  3. Travel: Round the circulation. Through the lungs and the left heart, then out to the arteries of the limbs and gut. Drug in the blood: very high; Drug effect: none. Monitor: Post-ROSC hypotension.
  4. Site of action: Alpha-1 receptors in the arterioles. Constricts arterioles (alpha-1) to raise mean arterial pressure, with a modest increase in contractility (beta-1) and little effect on rate. Close-up: Alpha-1 receptors in the arterioles. Drug in the blood: very high; Drug effect: moderate. Monitor: Post-ROSC hypotension.
  5. Effect: The effect. Arterioles narrow and the mean arterial pressure rises, with a small boost to contraction and little change in rate. Close-up: Alpha-1 receptors in the arterioles. Drug in the blood: very high; Drug effect: very high. Monitor: Pressure restored.
  6. Monitor: What the monitor shows. Little direct effect; reflex slowing of the rate is possible. Close-up: Alpha-1 receptors in the arterioles. Drug in the blood: very high; Drug effect: very high. Monitor: Pressure restored.
  7. Monitor: Remember. Target a MAP of 65 mm Hg or more after ROSC; hypotension worsens brain injury. Close-up: Alpha-1 receptors in the arterioles. Drug in the blood: very high; Drug effect: high. Monitor: Pressure restored.
Calcium chloride and gluconate For hyperkalemia and calcium-channel blocker toxicity

Hyperkalemia with a wide QRS. Watch it · Doses and cautions

  1. Give: Give. Calcium chloride 10%: 500–1000 mg (5–10 mL), IV/IO. Hyperkalemia with ECG changes. Calcium chloride irritates veins: use a large vein. Drug in the blood: none; Gap between rest and threshold: low; Serum potassium: very high. Monitor: Hyperkalemia: wide QRS.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Gap between rest and threshold: low; Serum potassium: very high. Monitor: Hyperkalemia: wide QRS.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Gap between rest and threshold: low; Serum potassium: very high. Monitor: Hyperkalemia: wide QRS.
  4. Site of action: Rest has crept up to threshold. High potassium outside the cells makes the resting potential less negative, close to threshold. Many sodium channels sit inactivated, so each beat spreads slowly: wide QRS, lost P waves, and in the end a sine wave. Close-up: Resting potential and threshold. Drug in the blood: very high; Gap between rest and threshold: low; Serum potassium: very high. Monitor: Hyperkalemia: wide QRS.
  5. Effect: Calcium raises the threshold. Extra calcium raises the threshold back, restoring the gap between rest and firing within minutes. Conduction recovers. Close-up: Threshold raised. Drug in the blood: very high; Gap between rest and threshold: high; Serum potassium: very high. Monitor: QRS narrower; peaked T remains.
  6. Monitor: The potassium has not moved. Look at the potassium: unchanged. Calcium protects the membrane; it lowers nothing, and its effect wears off. Next, shift potassium into the cells and arrange its removal. Close-up: Threshold raised. Drug in the blood: very high; Gap between rest and threshold: high; Serum potassium: very high. Monitor: QRS narrower; peaked T remains.
Sodium bicarbonate For specific causes, not routine

Hyperkalemia

Hyperkalemia. Watch it · Doses and cautions

  1. Give: Give. Sodium bicarbonate: 1 mEq/kg, IV/IO. Hyperkalemia, or the other specific causes; not for routine use in arrest. Drug in the blood: none; Serum potassium: very high; Potassium in the whole body: very high. Monitor: Hyperkalemia.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Serum potassium: very high; Potassium in the whole body: very high. Monitor: Hyperkalemia.
  3. Travel: Round the circulation. Through the lungs and the left heart, then out to the body's cells, most of them in muscle. Drug in the blood: very high; Serum potassium: very high; Potassium in the whole body: very high. Monitor: Hyperkalemia.
  4. Site of action: Potassium moves into the cells. Bicarbonate raises the blood's pH. Cells give up hydrogen ions to the blood and take potassium in to balance the charge, so serum potassium falls for a while. Close-up: Muscle cell and blood. Drug in the blood: very high; Serum potassium: high; Potassium in the whole body: very high. Monitor: Hyperkalemia, less severe.
  5. Effect: Other drugs shift it the same way. Insulin (given with glucose) and inhaled beta-2 agonists such as albuterol push potassium into cells by another route: they speed up the sodium–potassium pump. Calcium, given first, protects the heart while these work. Close-up: The sodium–potassium pump. Drug in the blood: very high; Serum potassium: moderate; Potassium in the whole body: very high. Monitor: Hyperkalemia, less severe.
  6. Monitor: Shifted, not removed. Every one of these only moves potassium. The total in the body has not changed, and it leaks back out as they wear off. Removal takes the kidneys, binders or dialysis. Close-up: The sodium–potassium pump. Drug in the blood: high; Serum potassium: moderate; Potassium in the whole body: very high. Monitor: Hyperkalemia, less severe.

Sodium-channel blocker

Sodium-channel blocker toxicity with a wide QRS. Watch it · Doses and cautions

  1. Give: Give. Sodium bicarbonate: 1 mEq/kg, IV/IO. Sodium-channel blocker overdose (for example a tricyclic) with a wide QRS. Drug in the blood: none; Sodium channels getting through: moderate. Monitor: Wide-QRS tachycardia.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Sodium channels getting through: moderate. Monitor: Wide-QRS tachycardia.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Sodium channels getting through: moderate. Monitor: Wide-QRS tachycardia.
  4. Site of action: Blocked sodium channels. The drug sits in the fast sodium channels of the heart. Phase 0 rises slowly and the impulse crawls through the ventricles: a wide QRS, hypotension and ventricular arrhythmias. Close-up: Sodium channels blocked by the drug. Drug in the blood: very high; Sodium channels getting through: moderate. Monitor: Wide-QRS tachycardia.
  5. Effect: Sodium load and a higher pH. A load of sodium outside the cell pushes more current through the channels that are still open, and a higher pH loosens the drug's grip on them. The upstroke speeds up again. Close-up: Sodium load. Drug in the blood: very high; Sodium channels getting through: high. Monitor: QRS narrower.
  6. Monitor: The QRS narrows. On the monitor the QRS narrows (and the terminal R wave in aVR shrinks on a 12-lead). Repeat by the QRS width and the blood gas: treat a cause, not a number. Close-up: Sodium load. Drug in the blood: very high; Sodium channels getting through: high. Monitor: QRS narrower.
Lipid emulsion (20%) For local anesthetic systemic toxicity

Local anesthetic systemic toxicity after a nerve block. Watch it · Doses and cautions

  1. Give: Give. Lipid emulsion (20%): 1.5 mL/kg of 20% over 2–3 minutes, then 0.25 mL/kg/min, IV/IO. Local anesthetic systemic toxicity: seizures, arrhythmias or arrest after a block or an injection. Drug in the blood: none; Drug effect: none. Monitor: Wide QRS, slow.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Wide QRS, slow.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Drug effect: none. Monitor: Wide QRS, slow.
  4. Site of action: The lipid sink. A circulating lipid phase draws lipid-soluble local anesthetic (bupivacaine above all) out of the heart and brain, a "lipid sink", and supplies the poisoned heart with fuel while the drug is cleared. Close-up: The lipid sink. Drug in the blood: very high; Drug effect: moderate. Monitor: Wide QRS, slow.
  5. Effect: The effect. As the drug is drawn off the sodium channels, conduction recovers; the lipid also feeds the poisoned muscle while the drug is cleared. Close-up: The lipid sink. Drug in the blood: very high; Drug effect: very high. Monitor: Recovering.
  6. Monitor: What the monitor shows. In LAST: a widening QRS, bradycardia, ventricular arrhythmias; these resolve as the drug is drawn out. Close-up: The lipid sink. Drug in the blood: very high; Drug effect: very high. Monitor: Recovering.
  7. Monitor: Remember. Stop the injection, call for help and the lipid kit, and start lipid at the first sign of serious toxicity. Close-up: The lipid sink. Drug in the blood: very high; Drug effect: high. Monitor: Recovering.
Glucagon For beta-blocker (and calcium-channel blocker) toxicity

Beta-blocker overdose: bradycardia and hypotension. Watch it · Doses and cautions

  1. Give: Give. Glucagon: 3–10 mg IV over 3–5 minutes (about 0.05–0.15 mg/kg), IV. Bradycardia and hypotension from a beta-blocker overdose. Drug in the blood: none; Drug effect: none. Monitor: Beta-blocker overdose.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Beta-blocker overdose.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Drug effect: none. Monitor: Beta-blocker overdose.
  4. Site of action: Glucagon receptors on heart cells. Glucagon acts on its own receptor on cardiac cells, which raises cAMP just as beta stimulation would. Close-up: Glucagon receptors on heart cells. Drug in the blood: very high; Drug effect: moderate. Monitor: Beta-blocker overdose.
  5. Effect: The effect. A beta-blocker cannot block it, so it can restore some rate and contractility when the beta receptors are occupied. Close-up: Glucagon receptors on heart cells. Drug in the blood: very high; Drug effect: very high. Monitor: Some response.
  6. Monitor: What the monitor shows. A faster sinus or escape rate and better conduction if it works; often a modest effect. Close-up: Glucagon receptors on heart cells. Drug in the blood: very high; Drug effect: very high. Monitor: Some response.
  7. Monitor: Remember. High-dose insulin, calcium and vasopressors are given alongside, not instead. Close-up: Glucagon receptors on heart cells. Drug in the blood: very high; Drug effect: high. Monitor: Some response.
Isoproterenol infusion A pure beta agonist that speeds the heart

Pause-dependent torsades recurring after magnesium. Watch it · Doses and cautions

  1. Give: Give. Isoproterenol infusion: 2–10 mcg/min, titrated to the heart rate, IV. Pause-dependent torsades that keeps coming back, as a bridge to overdrive pacing. Drug in the blood: none; Drug effect: none. Monitor: Slow rate, long QT.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Slow rate, long QT.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the heart's own blood supply, reaching the nodes and the muscle. Drug in the blood: very high; Drug effect: none. Monitor: Slow rate, long QT.
  4. Site of action: Beta-1 and beta-2 receptors. Stimulates beta-1 receptors (faster rate, faster conduction) and beta-2 receptors (vasodilation). Close-up: Beta-1 and beta-2 receptors. Drug in the blood: very high; Drug effect: moderate. Monitor: Slow rate, long QT.
  5. Effect: The effect. A faster heart rate shortens the QT, which is why it can stop pause-dependent torsades from recurring. Close-up: Beta-1 and beta-2 receptors. Drug in the blood: very high; Drug effect: very high. Monitor: Faster rate, shorter QT.
  6. Monitor: What the monitor shows. On the monitor: a faster sinus rate and a shorter QT. Close-up: Beta-1 and beta-2 receptors. Drug in the blood: very high; Drug effect: very high. Monitor: Faster rate, shorter QT.
  7. Monitor: Remember. For torsades that keeps coming back after magnesium: raise the rate, with isoproterenol or overdrive pacing. Close-up: Beta-1 and beta-2 receptors. Drug in the blood: very high; Drug effect: high. Monitor: Faster rate, shorter QT.
Naloxone Reverses opioid respiratory depression

Suspected opioid overdose: a pulse, but breathing slow and shallow. Watch it · Doses and cautions

  1. Give: Give. Naloxone: 4 mg, IN. Or 0.4 mg, titrated IM/IV, titrated. Ventilate first: oxygen and a bag-mask buy time the drug cannot. Drug in the blood: none; Drive to breathe: low. Monitor: Opioid overdose: slow breathing.
  2. Travel: To the heart. Absorbed through the lining of the nose into the veins, it is carried back to the right side of the heart. Drug in the blood: moderate; Drive to breathe: low. Monitor: Opioid overdose: slow breathing.
  3. Travel: Round the circulation. Through the lungs and the left heart, then up the carotid arteries to the brainstem. Drug in the blood: very high; Drive to breathe: low. Monitor: Opioid overdose: slow breathing.
  4. Site of action: Mu receptors in the brainstem. In the brainstem's breathing centre, opioid molecules occupy mu receptors and turn the drive to breathe down: breaths are slow and shallow, carbon dioxide climbs. Close-up: Mu receptor, respiratory centre. Drug in the blood: very high; Drive to breathe: low. Monitor: Opioid overdose: slow breathing.
  5. Effect: Naloxone pushes the opioid off. Naloxone binds the same receptors more tightly and displaces the opioid. It switches nothing on: it takes the brake off. Close-up: Naloxone in the mu receptor. Drug in the blood: very high; Drive to breathe: very high. Monitor: Breathing again.
  6. Monitor: Breathing returns. Breathing rate rises, the CO₂ trace shrinks back toward normal and saturation climbs. Correcting the hypoxia often settles the bradycardia. Withdrawal can be abrupt: agitation, vomiting. Close-up: Naloxone in the mu receptor. Drug in the blood: very high; Drive to breathe: very high. Monitor: Breathing again.
  7. Effect: It can wear off first. Naloxone is shorter acting than many opioids. As it is cleared the opioid can rebind: watch for re-sedation, and repeat every 2–3 minutes if no response. Close-up: The opioid rebinding. Drug in the blood: low; Drive to breathe: moderate. Monitor: Breathing slowing again.
Oxygen A drug with targets

After ROSC: titrating oxygen to a target. Watch it · Doses and cautions

  1. Give: Give. Oxygen: Titrate to SpO₂ 90–98%, inhaled. After ROSC: titrate to a target once saturation can be measured. Drug in the blood: none; Drug effect: none. Monitor: Hypoxemic.
  2. Travel: To the heart. Breathed in, it crosses into the blood in the lungs. Drug in the blood: moderate; Drug effect: none. Monitor: Hypoxemic.
  3. Travel: Round the circulation. Through the lungs and the left heart, then up the carotid arteries to the brainstem. Drug in the blood: very high; Drug effect: none. Monitor: Hypoxemic.
  4. Site of action: Oxygen to the tissues. Raises arterial oxygen content. Close-up: Oxygen to the tissues. Drug in the blood: very high; Drug effect: moderate. Monitor: Hypoxemic.
  5. Effect: The effect. In arrest, deliver the highest concentration available; once there is circulation, too much is harmful too, so titrate to a target. Close-up: Oxygen to the tissues. Drug in the blood: very high; Drug effect: very high. Monitor: Within target.
  6. Monitor: What the monitor shows. None directly; hypoxia drives bradycardia and ectopy. Close-up: Oxygen to the tissues. Drug in the blood: very high; Drug effect: very high. Monitor: Within target.
  7. Monitor: Remember. Give 100% until you can measure, then titrate. Close-up: Oxygen to the tissues. Drug in the blood: very high; Drug effect: high. Monitor: Within target.
Aspirin The first drug for ACS

Suspected acute coronary syndrome. Watch it · Doses and cautions

  1. Give: Give. Aspirin: 162–325 mg, chewed (non-enteric-coated), oral. Suspected acute coronary syndrome, as early as possible. Drug in the blood: none; Drug effect: none. Monitor: Chest pain.
  2. Travel: To the heart. Chewed, it is absorbed through the stomach and gut lining, passes the liver and reaches the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Chest pain.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the blocked artery. Drug in the blood: very high; Drug effect: none. Monitor: Chest pain.
  4. Site of action: Platelets on a ruptured plaque. Blocks thromboxane A2 production in platelets for their whole lifespan, so fewer platelets join the thrombus forming on a ruptured plaque. Close-up: Platelets on a ruptured plaque. Drug in the blood: very high; Drug effect: moderate. Monitor: Chest pain.
  5. Effect: The effect. Fewer platelets are recruited, so the clot grows more slowly and is less likely to block the artery completely. It does not dissolve the clot already there. Close-up: Platelets on a ruptured plaque. Drug in the blood: very high; Drug effect: very high. Monitor: No direct ECG change.
  6. Monitor: What the monitor shows. Nothing changes on the monitor: this drug works on the clot, not on the heart's electrical activity. Close-up: Platelets on a ruptured plaque. Drug in the blood: very high; Drug effect: very high. Monitor: No direct ECG change.
  7. Monitor: Remember. Chew it: a swallowed coated tablet takes far longer to work. Close-up: Platelets on a ruptured plaque. Drug in the blood: very high; Drug effect: high. Monitor: No direct ECG change.
Nitroglycerin Preload reduction for ischemic pain

Ongoing ischemic chest pain with an adequate blood pressure. Watch it · Doses and cautions

  1. Give: Give. Nitroglycerin: 0.4 mg sublingual, SL. Ongoing ischemic chest discomfort with an adequate blood pressure. Drug in the blood: none; Drug effect: none. Monitor: Ischemic pain.
  2. Travel: To the heart. Under the tongue it is absorbed straight into the veins, skipping the liver, and reaches the right heart quickly. Drug in the blood: moderate; Drug effect: none. Monitor: Ischemic pain.
  3. Site of action: Venous smooth muscle. Releases nitric oxide, which relaxes venous smooth muscle more than arterial: venous return (preload) falls, so wall stress and oxygen demand fall. Close-up: Venous smooth muscle. Drug in the blood: very high; Drug effect: moderate. Monitor: Ischemic pain.
  4. Effect: The effect. Coronary arteries dilate as well. With less stretch on the ventricle and better coronary flow, ischemic pain can ease; blood pressure falls, so check it before each dose. Close-up: Venous smooth muscle. Drug in the blood: very high; Drug effect: very high. Monitor: Pressure and pain easing.
  5. Monitor: What the monitor shows. None directly; relief of ischemia may resolve ST depression. Close-up: Venous smooth muscle. Drug in the blood: very high; Drug effect: very high. Monitor: Pressure and pain easing.
  6. Monitor: Remember. Inferior STEMI? Look at V4R before giving nitrates. Close-up: Venous smooth muscle. Drug in the blood: very high; Drug effect: high. Monitor: Pressure and pain easing.
Morphine and fentanyl Analgesia only when nitrates fail

ACS pain that persists despite nitrates. Watch it · Doses and cautions

  1. Give: Give. Morphine or fentanyl: Small titrated IV doses, IV. Chest pain in ACS that persists despite nitrates. Drug in the blood: none; Drug effect: none. Monitor: Pain, anxiety.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Pain, anxiety.
  3. Travel: Round the circulation. Through the lungs and the left heart, then up the carotid arteries to the brainstem. Drug in the blood: very high; Drug effect: none. Monitor: Pain, anxiety.
  4. Site of action: Mu receptors. Mu-receptor agonists: they relieve pain and anxiety and reduce sympathetic drive. Close-up: Mu receptors. Drug in the blood: very high; Drug effect: moderate. Monitor: Pain, anxiety.
  5. Effect: The effect. Less pain and anxiety means less sympathetic drive, so the heart rate and blood pressure ease; morphine also dilates veins. The drive to breathe falls too. Close-up: Mu receptors. Drug in the blood: very high; Drug effect: very high. Monitor: Comfortable.
  6. Monitor: What the monitor shows. On the monitor: none directly. Close-up: Mu receptors. Drug in the blood: very high; Drug effect: very high. Monitor: Comfortable.
  7. Monitor: Remember. Analgesia is a comfort measure, not a treatment for the occlusion. Close-up: Mu receptors. Drug in the blood: very high; Drug effect: high. Monitor: Comfortable.
Fibrinolytics (alteplase, tenecteplase, reteplase) Dissolve the clot when PCI or thrombectomy is too far away

STEMI, when PCI cannot be done in time. Watch it · Doses and cautions

  1. Give: Give. Fibrinolytic: Agent-specific weight-based regimens, IV. STEMI when primary PCI cannot be done in time. Drug in the blood: none; Drug effect: none. Monitor: Anterior STEMI.
  2. Travel: To the heart. Venous blood carries it back to the right side of the heart. Drug in the blood: moderate; Drug effect: none. Monitor: Anterior STEMI.
  3. Travel: Round the circulation. Through the lungs and the left heart, then into the blocked artery. Drug in the blood: very high; Drug effect: none. Monitor: Anterior STEMI.
  4. Site of action: The fibrin mesh of the clot. Convert plasminogen to plasmin, which cuts the fibrin mesh holding a thrombus together and reopens the artery. Close-up: The fibrin mesh of the clot. Drug in the blood: very high; Drug effect: moderate. Monitor: Anterior STEMI.
  5. Effect: The effect. Blood reaches the muscle again. But the drug cannot tell this clot from one sealing a vessel elsewhere, which is why bleeding is the main risk. Close-up: The fibrin mesh of the clot. Drug in the blood: very high; Drug effect: very high. Monitor: Reperfusion rhythm.
  6. Monitor: What the monitor shows. After STEMI lysis: ST resolution of 50% or more and reperfusion arrhythmias (accelerated idioventricular rhythm) suggest the artery has opened. Close-up: The fibrin mesh of the clot. Drug in the blood: very high; Drug effect: very high. Monitor: Reperfusion rhythm.
  7. Monitor: Remember. Time is muscle, and time is brain: the clock starts at symptom onset. Close-up: The fibrin mesh of the clot. Drug in the blood: very high; Drug effect: high. Monitor: Reperfusion rhythm.

Verify against current local protocol. Verify every energy and dose against your current local protocol and the device in use before relying on it.

The full 2025 guideline text could not be opened when this page was drafted; the 2025 changes listed were confirmed from summaries of AHA's published 2025 algorithms and highlights. Drug doses are the 2020 algorithm doses, which those 2025 algorithms keep.

Guidelines and sources

Reflects the AHA 2020 adult algorithms with the 2023 focused update, updated for the 2025 AHA Guidelines for CPR and ECC where the change could be confirmed; acute coronary syndromes follow the 2025 ACC/AHA guideline and stroke the 2026 AHA/ASA guideline.

Algorithms and doses follow the AHA 2020 Guidelines for CPR and ECC, adult algorithms (Part 3: Adult Basic and Advanced Life Support, Circulation 2020;142(suppl 2):S366–S468), checked for changes in:

  • 2023 AHA Focused Update on Adult Advanced Cardiovascular Life Support (Circulation 2024;149:e254–e273)
  • 2025 AHA Guidelines for CPR and ECC, Part 9: Adult Advanced Life Support

Changes in the 2025 guidelines reflected here:

  • Synchronized cardioversion of atrial fibrillation: an initial energy of at least 200 J with a biphasic defibrillator is now recommended, rather than a lower first shock.
  • The tachycardia algorithm refers to the device's recommended energy level rather than listing energies for each rhythm.
  • Intravenous access is preferred to intraosseous access as the first attempt in cardiac arrest.
  • Double sequential defibrillation and vector-change defibrillation for refractory VF remain of uncertain benefit.
  • Sotalol is no longer listed in the tachycardia algorithm; procainamide and amiodarone remain.
  • Routine calcium and sodium bicarbonate are not recommended in cardiac arrest; both are kept for specific causes.
  • After ROSC: titrate oxygen to an SpO₂ of 90–98%, keep the MAP at 65 mm Hg or more, and use deliberate temperature control (32–37.5 °C) for patients not following commands.
  • Sustained polymorphic VT in an adult gets an immediate unsynchronized shock at the defibrillation dose, with or without a pulse, because synchronization is unreliable. Torsades with a pulse also gets magnesium and treatment of the cause.

Sources:

  1. Panchal AR, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16 suppl 2):S366–S468.
  2. Perman SM, et al. 2023 American Heart Association Focused Update on Adult Advanced Cardiovascular Life Support. Circulation. 2024;149:e254–e273.
  3. Lavonas EJ, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning. Circulation. 2023;148:e149–e184.
  4. Part 7: Adult Basic Life Support. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  5. Part 9: Adult Advanced Life Support. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2):S538–S577.
  6. Part 10: Adult and Pediatric Special Circumstances of Resuscitation. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  7. Part 11: Post–Cardiac Arrest Care. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  8. Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771–e862.
  9. Prabhakaran S, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke (AHA/ASA). Stroke. 2026. doi:10.1161/STR.0000000000000513.

The full 2025 guideline text could not be opened when this page was drafted; the 2025 changes listed were confirmed from summaries of AHA's published 2025 algorithms and highlights. Drug doses are the 2020 algorithm doses, which those 2025 algorithms keep. All text and pictures here are original teaching material, not reproductions of AHA algorithms. Education only, not a treatment protocol.

Sources

Every source the site cites, with links

Report a correction

Tell us what looks wrong, ideally with a source. Reports go to a private tracking list; you get a ticket number.

Up to 2000 characters.

What is stored